Clinical Trial News and Research

RSS

Progesterone gel can reduce preterm birth in women with short cervix

A groundbreaking clinical study of a new method for preventing premature birth in millions of women each year, published in the medical journal Ultrasound in Obstetrics & Gynecology, shows that the rate of early preterm delivery in women can be reduced by 45 percent - simply by treating pregnant women at risk with a low-cost gel of natural progesterone during the midtrimester of pregnancy until term.

7 Apr 2011

New PSA test identifies men with prostate cancer more accurately

In a large multi-center clinical trial, a new PSA test to screen for prostate cancer more accurately identified men with prostate cancer -- particularly the aggressive form of the disease -- and substantially reduced false positives compared to the two currently available commercial PSA tests, according to newly published research from Northwestern Medicine.

7 Apr 2011

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced that it has successfully completed two Phase 1a clinical studies for AVL-292, its orally-available, selective inhibitor of Bruton's tyrosine kinase (Btk).

6 Apr 2011

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.

6 Apr 2011

Aptiv Solutions creates Adaptive Clinical Trials Innovation Center

Aptiv Solutions, a global biopharmaceutical and medical device development services company, announced today the creation of an Adaptive Clinical Trials Innovation Center.

6 Apr 2011

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.

6 Apr 2011

Device to treat resistant hypertension lowers blood pressure by 33 points

A device designed to treat people with resistant hypertension helped lower blood pressure by 33 points, a substantial drop that would otherwise require patients to take an additional three or four drugs, on top of this subgroup's usual regimen of up to five drugs, to control their difficult-to-treat condition.

6 Apr 2011

Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting

Pervasis Therapeutics, Inc. today announced preclinical data showing positive effects of PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, on controlling tumor growth and inhibiting metastases in an animal model of prostate cancer.

6 Apr 2011

Boston Scientific initiates clinical enrollment for INNOVA Self-Expanding Bare-Metal Stent System trial

Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

6 Apr 2011

FDA approves NeuroVasx cPAX Aneurysm Treatment System

NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.

6 Apr 2011

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011

MR patients treated with Abbott MitraClip system demonstrate clinical benefits of initial treatment at two years

Abbott today announced data from its EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study showing that patients with significant mitral regurgitation (MR) treated with the company's investigational percutaneous catheter-based MitraClip® system continue to demonstrate the clinical benefits of initial treatment shown at one year out to two years, including improvements in heart function and reductions in symptoms.

5 Apr 2011

Less-invasive catheter-based aortic valve replacement as safe and effective as open surgery

Less-invasive catheter-based aortic valve replacement has a similar one-year survival as open valve-replacement surgery for patients at high risk for surgery.

5 Apr 2011

OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting

OncoGenex Pharmaceuticals, Inc. announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011.

5 Apr 2011

HCRI, MAHVI present transcatheter aortic valve data in severe stenosis at ACC meeting

The Harvard Clinical Research Institute and Saint Luke's Mid America Heart and Vascular Institute today announced that Matthew R. Reynolds, M.D., Director of the Economics and Quality of Life Research Center at HCRI, presented results of a cost-effectiveness analysis of transcatheter aortic valve replacement versus standard therapy for severe aortic stenosis, as part of the opening plenary session on April 3 at the American College of Cardiology 60th Annual Scientific Session & Expo.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene,a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver over the weekend at the Internationales Congress Centrum in Berlin, Germany.

5 Apr 2011

Acamprosate can help treat patients with autism, Fragile X syndrome

In small, early clinical trials, adults and children with autism and Fragile X syndrome have shown improved communication and social behavior when treated with acamprosate, according to Craig Erickson, M.D., assistant professor of psychiatry at the Indiana University School of Medicine and chief of the Riley Hospital for Children Christian Sarkine Autism Treatment Center at Indiana University Health.

5 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Statins can help prevent risk of death from pneumonia

Taking statins could help prevent people dying from pneumonia, according to a study by the London School of Hygiene and Tropical Medicine.

5 Apr 2011

Clinical Trial News and Research

Progesterone gel can reduce preterm birth in women with short cervix

New PSA test identifies men with prostate cancer more accurately

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Aptiv Solutions creates Adaptive Clinical Trials Innovation Center

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Device to treat resistant hypertension lowers blood pressure by 33 points

Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting

Boston Scientific initiates clinical enrollment for INNOVA Self-Expanding Bare-Metal Stent System trial

FDA approves NeuroVasx cPAX Aneurysm Treatment System

Merck enters definitive agreement to acquire Inspire

MR patients treated with Abbott MitraClip system demonstrate clinical benefits of initial treatment at two years

Less-invasive catheter-based aortic valve replacement as safe and effective as open surgery

OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting

HCRI, MAHVI present transcatheter aortic valve data in severe stenosis at ACC meeting

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Acamprosate can help treat patients with autism, Fragile X syndrome

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Statins can help prevent risk of death from pneumonia

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer